Log in to search using one of your social media accounts:

 

Drug combination may improve impact of immunotherapy in head and neck cancer
(University of California - San Diego) Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy's effectiveness. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2017 Category: International Medicine & Public Health Source Type: news

Short dental implants: A scoping review of the literature for patients with head and neck cancer
ConclusionsShort dental implants (6 mm to 8 mm) can be used successfully to support single or multiple fixed reconstructions or overdentures in atrophic maxillae and mandibles. The use of short dental implants lessens the need for advanced and complicated surgical bone augmentation procedures, which reduces complications, costs, treatment time, and morbidity. Short implants could be an alternative in the rehabilitation of patients with cancer. (Source: Dental Technology Blog)
Source: Dental Technology Blog - September 20, 2017 Category: Dentistry Source Type: news

Tailored Treatment for Head-and-Neck Cancer Mystery
Treatment TermsHead and Neck Cancer Overview Rob Vaughn found a lump on his neck that turned out to be cancer that had spread from somewhere else in his body. The trouble was, doctors couldn ’t find the original site of the cancer. That made his treatment decisions difficult -- until two Duke specialists offered him options, including the option for watchful waiting instead of extensive treatment. Hero Image20170914_robvaughn_neckcancer_083_herocrop.jpg Preview Image Content Blocks Header A Search for the Source of Cancer ContentVaughn, a Charlotte, NC, father of two, was 47 and in good health when he felt th...
Source: dukehealth.org: Duke Health News - September 15, 2017 Category: Consumer Health News Authors: mf205 at duke.edu Source Type: news

Tactile Medical shareholders ready $109 million offering
Tactile Systems Technology said this week that its investors have priced a new offering, looking to raise approximately $109 million. In the offering, investors in the Minneapolis, Minn.-based company will look to offer 3.3 million shares of common stock at approximately $33 per share. The offering will also include an underwriters option to purchase an additional 495,000 shares, which could bring in an additional $16.3 million. Tactile said it will receive no proceeds from the offering, which is expected to close today. William Blair & Co. and Piper Jaffray & Co. are acting as joint book runners, with Cannaco...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Tactile Systems Technology Source Type: news

Monopar receives licence to develop Onxeo ’s Validive oral mucositis treatment
Onxeo has granted a global exclusive licence to Monopar Therapeutics for its Validive (clonidine mucoadhesive buccal) tablet used to treat severe oral mucositis induced by radiotherapy or chemotherapy in patients suffering from head and neck cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 13, 2017 Category: Pharmaceuticals Source Type: news

Cancer drug stimulates tripolar mode of mitosis
(Helmholtz Zentrum M ü nchen - German Research Center for Environmental Health) Taxanes inhibit cell division and make cancer cells sensitive to radiation therapy. A current study has investigated the underlying mechanisms of this action - and which biomarkers may be useful for predicting the success of therapy. The study, published in the journal Oncogene, was carried out within the framework of the Clinical Cooperation Group Personalized Radiotherapy in Head and Neck Cancer at Helmholtz Zentrum M ü nchen and Munich University Hospital. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 12, 2017 Category: Biology Source Type: news

KEYNOTE-040 evaluates pembrolizumab in head and neck cancer
(European Society for Medical Oncology) Immunotherapy with the checkpoint inhibitor pembrolizumab may be a better option than standard treatments for patients whose head and neck cancer has spread, or recurred after an initial round of chemotherapy, according to results of the Keynote-040 trial presented at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2017 Category: Cancer & Oncology Source Type: news

World Trade Center responders might face greater risk of HPV throat and tongue cancer
(Rutgers University) Researchers at Rutgers University -- investigating the causes of head and neck cancers in World Trade Center rescue and recovery workers -- will take the lead in a study to determine whether the responders are at a greater risk for human papillomavirus (HPV)-related throat and tongue cancer because of their exposure to toxic dust and debris. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2017 Category: International Medicine & Public Health Source Type: news

From bed to bench and back to bed: Mimicking how HPV-positive cancer responds to treatment
(Medical University of South Carolina) Patients with head and neck cancer who are also positive for human papilloma virus (HPV) are known to have a better prognosis compared to patients with HPV-negative disease, independent of therapeutic intervention. Researchers at the Medical University of South Carolina Hollings Cancer Center have discovered one reason why and have identified a peptide that, in preclinical studies, can act on the identified mechanism to improve outcomes in HPV-negative head and neck cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 7, 2017 Category: Biology Source Type: news

Physician experts highlight research ahead of Otolaryngology's annual meeting
(American Academy of Otolaryngology - Head and Neck Surgery) The latest research on patient preferences, quality-of-life, ear health, thyroidectomy, and other topics related to the specialty of otolaryngology will be presented in Chicago, IL, Sept. 10-13, during the AAO-HNSF 2017 Annual Meeting& OTO Experience. The 2017 Annual Meeting includes hundreds of research presentations. All abstracts to be presented are now available online. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 1, 2017 Category: Cancer & Oncology Source Type: news

After Skull Base Tumor, Dancer/Model Takes on Law School
Treatment TermsSkull base tumor Author Karen Doss Bowman Overview Victoria Vesce had surgery and 28 rounds of radiation for rare tumors in the base of her skull and in her neck. Four days after her last radiation treatment, she started law school. Hero Image20170809.vesce_.victoria.03.blog_.jpg Preview Image Content Blocks Section Header Image/Videovesce_honeybee_blog.jpg Section Features Images/Media Text Content Section Header Image/Videovesce_blog_secondary3.jpg Section Features Images/Media Text Content Header A Regional Destination for Rare Head and Neck Tumors ContentPatients from throughout the Sou...
Source: dukehealth.org: Duke Health News - August 23, 2017 Category: Consumer Health News Authors: mf205 at duke.edu Source Type: news

Cel-Sci raises $3.5m for head and neck cancer immunotherapy
Cel-Sci (NYSE:CVM) said today that it inked an agreement with institutional investors for a $3.5 million registered direct offering. The company said it plans to offer 1.75 million shares of common stock at $2.00 apiece. In a private placement, Cel-Sci will issue warrants to buy up to 1.75 million shares of common stock. For each share of stock purchased in the registered direct offering, investors in the private placement will receive an unregistered warrant to buy one share of common stock, which have an exercise price of $2.30 apiece. Get the full story at our sister site, Drug Delivery Business News...
Source: Mass Device - August 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Funding Roundup Oncology Pharmaceuticals Wall Street Beat cel-sci Source Type: news

Nutlin-3, a p53-Mdm2 antagonist for nasopharyngeal carcinoma treatment
(Bentham Science Publishers) Nasopharyngeal carcinoma (NPC) is a form of head and neck cancer that is highly prevalent among men in the populations of Southern China and Southeast Asia. This review will discuss the potential use of Nutlin-3 as a p53-activating drug and the future directions of its clinical research for NPC treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 23, 2017 Category: Cancer & Oncology Source Type: news

Study provides insight into link between two rare tumor syndromes
FINDINGSUCLA researchers have discovered that timing is everything when it comes to preventing a specific gene mutation in mice from developing rare and fast-growing cancerous tumors, which also affects young children. This mutation can also cause a benign tumor condition in humans in adulthood.The scientists found that when one tumor suppressor gene is turned off or inactivated during early stages of a developing mouse embryo, it induces the formation of a malignant tumor. The research demonstrates that this type of malignant tumor will not form if the gene is inactivated during later stages of nerve development. However,...
Source: UCLA Newsroom: Health Sciences - August 21, 2017 Category: Universities & Medical Training Source Type: news

FDA lifts hold on Cel-Sci's clinical trial for head and neck cancer drug
The U.S. Food and Drug Administration lifted a partial hold it placed nearly a year ago on a clinical trial for a head and neck cancer drug from Vienna-based Cel-Sci Corp. The company announced Monday morning it has received the go-ahead to resume the phase 3 clinical trial of immunotherapy drug Multikine. Cel-Sci had brought on 926 patients out of a desired 1,273 when the hold was put in place in September. The FDA instituted the hold because of an unreasonable an d significant risk of illness… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 14, 2017 Category: American Health Authors: Drew Hansen Source Type: news

Prevention of HPV-Related Oral Cancer by Dentists: Assessing the Opinion of Dutch Dental Students
Journal of Cancer Education pp 1 –8AbstractThe aim of this study is to assess dental students ’ opinions of the dentists’ role in primary prevention of human papillomavirus (HPV)-related oral cancer using a cross-sectional web-based survey. A questionnaire, containing questions about knowledge of HPV and oral cancer, confidence in head and neck examination and role of the dentist in preventing HPV-related oral cancer, was sent to all students of the Academic Centre of Dentistry Amsterdam (n = 912). One hundred and twenty-six (n = 126) students completed the questionnaire. Significantly...
Source: Dental Technology Blog - August 2, 2017 Category: Dentistry Source Type: news

Adherence to Quality Metrics Could Improve Head and Neck Cancer Survival
Adherence to each of five quality metrics for head and neck squamous cell carcinoma was associated with a reduced risk for death. (Source: CancerNetwork)
Source: CancerNetwork - July 31, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Head & Neck Cancer News Source Type: news

Merck immunotherapy fails to improve survival in head and neck cancer
(Reuters) - Merck& Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

New Data Show TomoTherapy(R) System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function SUNN... Devices, Oncology Accuray, TomoTherapy, radiosurgery, radiotherapy, RapidArc (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 20, 2017 Category: Pharmaceuticals Source Type: news

Accuray touts study data in head-to-head between TomoTherapy and Varian ’ s RapidArc
Accuray (NSDQ:ARAY) today released data from a prospective study comparing its TomoTherapy intensity-modulated radiation therapy system with Varian Medical‘s (NYSE:VAR), RapidArc radiotherapy system, touting a higher survival rate for patients treated with its TomoTherapy system. Results from the study were published last month in the International Journal of Radiation Oncology – Biology – Physics. Accuray said that the 166-patient, multi-center study was the 1st to prospectively compare clinical outcomes across radiation platforms. In the study, 74 individuals were treated with the TomoTherapy...
Source: Mass Device - July 20, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Oncology Accuray Inc. Varian Medical Systems Source Type: news

7 medtech stories we missed this week: July 14, 2017
[Image from unsplash.com]From Novarad touting its VR-surgical guidance system to Zynex paying off its $2.2M loan, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Stimwave announces first patient in Brazil Stimwave announced in a July 5 press release that its first patients in Brazil have received Stimwave’s wireless pain relief device treatment for chronic pain. The patients are expected to receive the neuromodulation treatment as an alternative to opioid pain relief. The devices created by Stimwave deliver small pulses of energy to specific nerves to trigger a reac...
Source: Mass Device - July 14, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Clinical Trials Diabetes Diagnostics Imaging Neuromodulation/Neurostimulation Pain Management Research & Development American Red Cross Nemaura Medical Novarad Owlstone Medical Stimwave Tactical Medical Zynex Inc. Source Type: news

Mesothelioma Clinical Trial Combines Immunotherapy Drugs
Dr. Tawee Tanvetyanon at the Moffitt Cancer Center in Tampa rarely sounds this enthused about the future prospects for patients with pleural mesothelioma. Finally, he has something promising to offer. Tanvetyanon is the principal investigator of a much-anticipated phase II clinical trial involving an immunotherapy drug combination with considerable potential for extending survival. “This is exciting. We now can offer something with realistic hope,” he told Asbestos.com. “We haven’t had anything like this for mesothelioma in a long time. I really look forward to speaking with these patients now.&rdqu...
Source: Asbestos and Mesothelioma News - July 13, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center Aduro Biotech CRS-207 Dr. Tawee Tanvetyanon FDA approval Keytruda improving mesothelioma prognosis Merck mesothelioma chemotherapy mesothelioma clinical trials mesothelioma immunotherapy moffitt cancer center m Source Type: news

Three-Weekly Cisplatin Superior to Weekly Dose in Head and Neck Cancer
Three-weekly cisplatin is superior to a weekly dose in preventing locoregional relapse when combined with radiotherapy in head and neck squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - July 3, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Head & Neck Cancer News Source Type: news

NIDCR Science News
Having trouble viewing this email? View it as a Web page. Delivering a One-Two Punch to Head and Neck CancerUniversity of California, Los Angeles • June 27, 2017 Blocking Yeast-Bacteria Interaction May Prevent Severe Biofilms that Cause Childhood Tooth Decay University of Pennsylvania • June 20, 2017 Sugar-coated Nanomaterial Excels at Promoting Bone Growth Northwestern University • June 19, 2017 Artificial Cartilage Under Tension as Strong as Natural University of California Davis &bu...
Source: NIDCR Science News - June 30, 2017 Category: Dentistry Source Type: news

Nivolumab Maintained QOL in Advanced Squamous Cell Head and Neck Cancer
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with the checkpoint inhibitor nivolumab were able to maintain baseline levels of quality of life. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Head & Neck Cancer News Source Type: news

Reduced Cancer - Independent Life Expectancy in Head, Neck Cancer
Cancer - independent life expectancy 6.5 years shorter for patients with head and neck cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 27, 2017 Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Internal Medicine, Nursing, Oncology, ENT, Pathology, Pulmonology, Radiology, Surgery, Journal, Source Type: news

Head and neck cancer cured with THIS treatment: Swollen glands were only symptoms
HEAD and neck cancers include cancers of the nose, mouth and throat and there are more than 10,000 cases diagnosed in the UK every year. (Source: Daily Express - Health)
Source: Daily Express - Health - June 24, 2017 Category: Consumer Health News Source Type: news

Immunotherapy kinder than chemotherapy for patients with head and neck cancer
(Institute of Cancer Research) The immunotherapy nivolumab is kinder than chemotherapy for people with advanced head and neck cancer -- easing many of the negative effects of the disease on patients' quality of life. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 23, 2017 Category: International Medicine & Public Health Source Type: news

Neoadjuvant Pembrolizumab Promising in Head and Neck Cancer Neoadjuvant Pembrolizumab Promising in Head and Neck Cancer
The data are early and the cohort small, but use in the neoadjuvant and adjuvant setting showed antitumor activity.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Treatment of Head and Neck Paragangliomas Treatment of Head and Neck Paragangliomas
Is first-line treatment for carotid body tumors the same as that for jugular and vagal paragangliomas?Cancer Control: Journal of the Moffitt Cancer Center (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Galera enrols last patient in Phase IIb trial of GC4419 to treat oral mucositis
US-based biotechnology company Galera Therapeutics has concluded enrolment in the Phase IIb clinical trial of GC4419 for the treatment of oral mucositis (OM) in patients with head and neck cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - June 18, 2017 Category: Pharmaceuticals Source Type: news

New UPMC Hillman Cancer Center leader named
UPMC Hillman Cancer Center has named Dr. Robert L. Ferris as its new director, effective July 1. Ferris, who has worked for the Hillman Cancer Center for 15 years, is a nationally known immunotherapy expert. He will replace Dr. Nancy Davidson, who left last year for a job in Washington State. Ferris is chief of UPMC's Division of Head and Neck Oncologic Surgery, co-leader of the Cancer Immun ology Program and associate director for translational research/co-director of the Tumor Microenvironment… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 16, 2017 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Tumor PD-L2 expression may predict patient response to anti-PD-1 immunotherapy
(American Association for Cancer Research) PD-L2 protein expression in human tumors was associated with clinical response to pembrolizumab (Keytruda), an anti-PD-1 immunotherapy, independent of PD-L1 expression, in patients with head and neck squamous cell carcinoma (HNSCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2017 Category: International Medicine & Public Health Source Type: news

HPV Vaccination Prevents Cancers in Men, Too
For years, scientists have touted the HPV vaccination ’s power to reduce cervical cancer in women. Now, during Men’s Health Week, Texas physicians urge men to get vaccinated against HPV to prevent cancers. HPV causes several cancers in men and women, including oropharyngeal (cancers of the head and neck such as the throat and mouth), penile, anal, cervical and vaginal. Some cases are fatal. (Source: TMA News Room)
Source: TMA News Room - June 14, 2017 Category: Consumer Health News Source Type: news

Role for Afatinib in p16-Negative Head and Neck Cancer?
This video reviews results of LUX-Head& Neck 2, a randomized phase III trial that studied afatinib as adjuvant therapy in patients with unresected squamous cell head and neck cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2017 Category: Cancer & Oncology Authors: Barbara Burtness, MD Tags: Conferences/ASCO Street Team Head & Neck Cancer News Source Type: news

MD Anderson and Hitachi to collaborate in research for treatment of oropharyngeal cancer of the head and neck
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have entered into an agreement to collaborate on research for a unique randomized clinical trial comparing the outcomes and side-effects of intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of oropharyngeal cancer of the head and neck. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 7, 2017 Category: International Medicine & Public Health Source Type: news

Bevacizumab Improves Responses, PFS in Advanced Head and Neck Cancer
This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Barbara Burtness, MD Tags: Conferences/ASCO Street Team Head & Neck Cancer News Source Type: news

Science Signaling Podcast for 6 June 2017: Calcium signaling and dry mouth
Abstract This Podcast features a conversation with Indu Ambudkar, senior author of a Research Resource that appears in the 6 June 2017 issue of Science Signaling, about how activation of the cation channel TRPM2 is involved in radiation-induced dry mouth. Patients who receive radiation therapy for head and neck cancers often develop dry mouth as a side effect, and this condition is frequently permanent. Radiation does not kill cells in the salivary gland, yet it causes the acinar cells of the gland to reduce the amount of saliva they secrete. Liu et al. found that radiation-induced activation of the cation channel TRPM2 tr...
Source: Signal Transduction Knowledge Environment - June 6, 2017 Category: Science Authors: Ambudkar, I., VanHook, A. M. Tags: STKE Podcasts Source Type: news

Highlight: Understanding radiation sialadenitis
A nonapoptotic function of caspase-3 underlies the salivary gland complications of radiation therapy of head and neck cancers. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - June 6, 2017 Category: Science Authors: Yaffe, M. B. Tags: STKE Editors ' Choice Source Type: news

DNA vaccine with immunotherapy may treat HPV cancers
A new vaccine therapy has the potential to generate immune responses in patients with head and neck squamous cell carcinoma in HPV patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 31, 2017 Category: Consumer Health News Source Type: news

NIDCR Science News
Having trouble viewing this email? View it as a Web page. Study Redefines HPV-related Head and Neck Cancers​ Virginia Commonwealth University • May 22, 2017​ Grape Seed Extract Could Extend Life of Resin Fillings​​ University of Illinois, Chicago • May 9, 2017​ Scientists Uncover Interactions Between Bacteria that Infect the Lungs in Cystic Fibrosis University of Alabama, Birmingham • April 27, 2017 Mouse Teeth Providing New Insights into Tissue Regeneration Un...
Source: NIDCR Science News - May 31, 2017 Category: Dentistry Source Type: news

Moffitt improves radiation therapy for head and neck patients
(H. Lee Moffitt Cancer Center& Research Institute) The researchers are able to use the radiosensitivity index within a mathematical framework to select the optimum radiotherapy dose for each patient based on their individual tumor biology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2017 Category: Cancer & Oncology Source Type: news

Immunotherapy with DNA vaccine shows promise for HPV-related head and neck cancer
(University of Pennsylvania School of Medicine) A novel vaccine therapy can generate immune responses in patients with head and neck squamous cell carcinoma (HNSCCa), according to researchers at the Abramson Cancer Center of the University of Pennsylvania. The treatment specifically targets human papillomavirus (HPV), which is frequently associated with HNSCCa, to trigger the immune response. Researchers will present the results of their pilot study during the 2017 American Society of Clinical Oncology Annual Meeting in Chicago (Abstract #6073). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2017 Category: Cancer & Oncology Source Type: news

Penn studies show hope for multiple cancers with pembrolizumab combination therapies
(University of Pennsylvania School of Medicine) The combination of pembrolizumab and the checkpoint inhibitor known as epacadostat is leading to promising responses and is generally well tolerated in patients with triple-negative breast cancer, non-small cell lung cancer, squamous cell cancer of the head and neck, and several other cancers, according to researchers from the Abramson Cancer Center of the University of Pennsylvania. Their findings also showed that adding pembrolizumab to standard therapies for breast cancer improved the number of patients achieving a pathological complete response. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 30, 2017 Category: International Medicine & Public Health Source Type: news

Tactile Systems launches Flexitouch lymphedema device
Tactile Systems Technology said today it launched its Flexitouch device designed to treat lymphedema of the head and neck, touting it as the 1st and only pneumatic compression therapy approved for the condition. The Flexitouch device is designed to use pneumatic compression to stimulate the lymphatic system to deliver non-invasive, self-delivered therapy for lymphedema, which is a common result of head and neck cancer and their treatments, the Minneapolis, Minn.-based company said.   “We are thrilled with these positive results demonstrating that the Flexitouch system can help head and neck lymphedema patie...
Source: Mass Device - May 26, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Oncology Pain Management Tactile Systems Technology Source Type: news

Study redefines HPV-related head and neck cancers
(Virginia Commonwealth University) Much of what we thought we knew about the human papilloma virus (HPV) in HPV-related head and neck cancers may be wrong, according to a newly published study by Virginia Commonwealth University (VCU) researchers that analyzed data from The Human Cancer Genome Atlas. Head and neck cancers involving HPV are on the rise, and many experts believe we are seeing the start of an epidemic that will only get worse in the coming years. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 22, 2017 Category: Biology Source Type: news

Latest Keytruda Approval Promising for Mesothelioma Patients
The U.S. Food and Drug Administration (FDA) expanded its approval of pembrolizumab for first-line treatment of metastatic non-small cell lung cancer last week, moving it closer to becoming a viable treatment option for patients with pleural mesothelioma. Pembrolizumab is marketed by Merck & Co. under the brand name Keytruda. It helps the body’s immune system detect and destroy cancer cells. The FDA approved its first-line use in combination with pemetrexed and carboplatin, two chemotherapy agents used regularly for mesothelioma. Pembrolizumab, the most well-known immunotherapy drug, is being studied for use with...
Source: Asbestos and Mesothelioma News - May 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: carboplatin chemotherapy for mesothelioma Dr. Raymond Wong Dr. Tawee Tanvetyanon FDA approval Keytruda first line treatment for mesothelioma Hodgkin lymphoma jimmy carter keytruda clinical trial keytruda for mesothelioma melanoma Mer Source Type: news

HPV Vaccine May Also Prevent Cancers Affecting Men
Study finds the cervical cancer vaccine cuts infection for viruses tied to oral, head and neck cancers (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 18, 2017 Category: Cancer & Oncology Tags: Infections, Oncology, Reproductive Medicine, News, Source Type: news

HPV Vaccine May Also Prevent Cancers Affecting Men
Study finds the cervical cancer vaccine cuts infection for viruses tied to oral, head and neck cancersSource: HealthDay Related MedlinePlus Pages: HPV, Head and Neck Cancer, Men's Health (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 18, 2017 Category: Consumer Health News Source Type: news

HPV Vaccine May Also Prevent Cancers Affecting Men
THURSDAY, May 18, 2017 -- The same vaccine that cuts the risk of cervical cancer in women might also lower the chances of head and neck cancers in men, new research suggests. In addition to being linked to cervical cancer, the human papillomavirus... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2017 Category: General Medicine Source Type: news